Bisphosphoglycerate mutase, EC 5.4.2.4, BPGM, 2,3-bisphosphoglycerate mutase erythrocyte, 2,3-bisphosphoglycerate synthase, BPG-dependent PGAM.
BPGM antibody was purified from mouse ascitic fluids by protein-A affinity chromatography.
PA2E11AT.
Anti-human BPGM mAb, is derived from hybridization of mouse F0 myeloma cells with spleen cells from BALB/c mice immunized with recombinant human BPGM amino acids 1-259 purified from E. coli.
BPGM (2,3-bisphosphoglycerate mutase) plays a crucial role in regulating hemoglobin oxygen affinity by controlling the levels of its allosteric effector 2,3-bisphosphoglycerate (2,3-BPG). This enzyme exhibits both synthase and mutase (EC 5.4.2.11) activities in erythrocytes, making it essential for oxygen transport regulation. Understanding BPGM function is critical for studies of erythrocyte metabolism, hemoglobin-oxygen binding dynamics, and related hematological disorders. The protein's molecular functions in controlling oxygen delivery to tissues make it a significant target for research into hypoxic conditions, altitude adaptation, and certain anemias .
The majority of commercially available BPGM antibodies are rabbit polyclonal antibodies raised against various epitopes of human BPGM. These include antibodies targeting different regions of the protein, such as the N-terminal region, C-terminal region, or central domains. Full-length antibodies recognize amino acids 1-259, while others target specific segments (e.g., AA 85-216 or AA 230-259). Most are unconjugated and suitable for multiple applications including Western blotting, immunocytochemistry, and immunofluorescence. The polyclonal nature of these antibodies provides robust detection across multiple epitopes but may introduce variability between lots .
While human reactivity is consistently reported across BPGM antibodies, cross-reactivity with other species varies by antibody. Some antibodies demonstrate reactivity only with human samples, while others show cross-reactivity with mouse samples. More broadly reactive antibodies may recognize BPGM in rat, cow, guinea pig, horse, rabbit, bat, and monkey samples, reflecting conservation of epitopes across species. When selecting an antibody for non-human research models, verifying the specific cross-reactivity profile is essential. Some antibodies, particularly those targeting highly conserved functional domains of BPGM, offer greater cross-species applicability .
BPGM antibodies have been validated for multiple experimental techniques, including:
Western Blotting (WB): Detecting BPGM at the expected 30 kDa molecular weight
Immunocytochemistry (ICC): Localizing BPGM within cellular compartments
Immunofluorescence (IF): Visualizing BPGM distribution patterns in fixed cells
Enzyme-Linked Immunosorbent Assay (ELISA): Quantifying BPGM protein content
Immunohistochemistry (IHC): Detecting BPGM in tissue sections
The most extensively validated applications are Western blotting and immunofluorescence, with established protocols for cell lines including 293T, A431, H1299, and HeLa .
For optimal Western blot detection of BPGM:
Sample preparation: Use whole cell lysates from relevant sources (293T, A431, H1299 cells have been validated)
Gel selection: 12% SDS-PAGE provides appropriate resolution for the 30 kDa BPGM protein
Antibody dilution: Begin with 1:1000 dilution for primary antibody incubation
Protein loading: 30 μg of whole cell lysate per lane has been demonstrated effective
Detection system: Both chemiluminescence and fluorescent secondary antibodies are suitable
Controls: Include positive control lysates with known BPGM expression
Blocking: Use 5% non-fat milk or BSA to minimize background
Researchers should anticipate a band at approximately 30 kDa, which is the predicted molecular weight for BPGM .
For immunofluorescence applications:
Fixation: Paraformaldehyde fixation has been validated for BPGM detection
Antibody dilution: Use a higher concentration (approximately 1:100) than for Western blotting
Permeabilization: Ensure appropriate membrane permeabilization for antibody access
Counterstaining: DAPI or other DNA probes help visualize cellular context
Controls: Include antibody omission controls to assess background
Mounting: Use anti-fade mounting medium to preserve signal
Imaging: Confocal microscopy may provide better resolution of subcellular localization
HeLa cells have been successfully used for immunofluorescence detection of BPGM as demonstrated in the literature .
Based on published methodologies, an ELISA system for BPGM quantification can be established following these guidelines:
Antibody selection: Use a polyclonal anti-BPGM antibody with demonstrated specificity
Standard curve: Generate using recombinant human BPGM (rBPGM) protein
Assay range: The system can be reliable between 0.1 to 10 ng/mL of BPGM
Specificity validation: Confirm absence of cross-reactivity with homologous proteins like B-type phosphoglycerate mutase
Sample preparation: Standardize erythrocyte lysis procedures
Quality control: Aim for coefficient of variation under 1.5% for reproducibility
Reference range establishment: Normal values in human whole blood are approximately 56.3 ± 9.7 μg/mL
This approach enables quantitative assessment of BPGM protein levels for comparison across samples or experimental conditions .
BPGM antibodies provide powerful tools for investigating erythrocyte metabolism and function:
Quantitative analysis: Measure BPGM protein levels in erythrocytes using ELISA or Western blotting
Comparative studies: Assess BPGM expression across different physiological states (exercise, altitude, disease)
Enzymopathy detection: Combine protein detection with activity assays to identify functional deficiencies
Correlation studies: Relate BPGM protein levels to 2,3-BPG concentrations and hemoglobin oxygen affinity
Genetic variation impact: Examine how BPGM polymorphisms affect protein expression and function
Developmental studies: Track BPGM expression changes during erythrocyte maturation
Pathophysiological investigation: Study BPGM alterations in hematological disorders
These approaches can help elucidate the role of BPGM in regulating oxygen transport under normal and pathological conditions .
When addressing potential cross-reactivity issues:
Epitope selection: Choose antibodies targeting unique regions of BPGM with minimal homology to related proteins
Validation approaches: Perform peptide competition assays to confirm specificity
Control inclusion: Use recombinant human B-type phosphoglycerate mutase as a negative control
Purification methods: Consider antibody affinity purification against the specific target
Stringency optimization: Adjust washing conditions and blocking agents to reduce non-specific binding
Multiple antibody validation: Confirm findings using antibodies targeting different BPGM epitopes
Technical alternatives: Consider mass spectrometry-based approaches for absolute confirmation
The search results indicate that properly validated antibodies show no cross-reaction with the highly homologous B-type phosphoglycerate mutase, suggesting good specificity can be achieved .
When encountering inconsistent results:
Antibody validation: Verify antibody specificity using positive and negative controls
Sample preparation: Ensure consistent protein extraction and handling procedures
Protein degradation assessment: Check for proteolytic degradation with protease inhibitors
Lot-to-lot variation: Compare results across different antibody lots when possible
Protocol standardization: Maintain consistent incubation times, temperatures, and buffer compositions
Quantification methods: Use appropriate loading controls for Western blots
Expression level considerations: Be aware that BPGM expression varies between tissues and cell types
Technical replication: Perform multiple independent experiments to confirm findings
Implementing these approaches can help distinguish between technical artifacts and true biological variation .
For comprehensive BPGM research, consider integrating these complementary approaches:
Enzyme activity assays: Correlate BPGM protein levels with functional activity
2,3-BPG measurement: Quantify the product of BPGM activity to establish functional relationships
Oxygen-hemoglobin dissociation curves: Link BPGM expression to physiological oxygen binding
Genetic analysis: Sequence BPGM to identify polymorphisms or mutations affecting function
Metabolomic profiling: Examine broader impacts on erythrocyte metabolism
Protein-protein interaction studies: Identify BPGM binding partners
Transcriptional analysis: Investigate BPGM gene regulation under different conditions
Structural studies: Relate antibody binding epitopes to protein functional domains
This multi-technique approach provides a more comprehensive understanding of BPGM biology than antibody-based detection alone .
A robust experimental design should include these controls:
Positive controls: Cell lysates with confirmed BPGM expression (293T, A431, H1299 cells)
Negative controls: Samples with minimal BPGM expression
Antibody controls: Primary antibody omission to assess secondary antibody specificity
Isotype controls: Irrelevant antibodies of the same isotype to evaluate non-specific binding
Loading controls: Housekeeping proteins to normalize expression levels
Peptide competition: Pre-incubation with immunizing peptide to confirm specificity
Recombinant protein standards: Purified BPGM protein for quantification references
These controls help distinguish specific signals from technical artifacts and enable reliable data interpretation .
When interpreting BPGM antibody results in oxygen transport research:
Context consideration: Relate BPGM protein levels to physiological or pathological context
Functional correlation: Establish relationships between BPGM expression, 2,3-BPG levels, and oxygen affinity
Cell-specific expression: Account for erythrocyte-specific expression patterns
Environmental factors: Consider how hypoxia, pH, and other factors affect BPGM expression
Species differences: Recognize variations in BPGM structure and function across species
Developmental stage: Account for changes in BPGM expression during erythrocyte maturation
Pathological implications: Interpret results in context of disease mechanisms where oxygen transport is compromised
This multifaceted interpretation approach helps translate molecular findings to physiological significance .
When extending BPGM research across species:
Antibody selection: Choose antibodies validated for cross-species reactivity or targeting highly conserved epitopes
Sequence alignment: Compare BPGM protein sequences across species to identify conserved regions
Epitope mapping: Determine if the antibody's target sequence is preserved in the species of interest
Validation requirements: Perform species-specific validation regardless of manufacturer claims
Control inclusion: Use tissue from the target species with known BPGM expression patterns
Dilution optimization: Adjust antibody concentrations for species-specific applications
Protocol adaptation: Modify fixation, extraction, or detection methods for species-specific tissues
These considerations ensure reliable detection of BPGM across experimental models from different species .
BPGM antibody applications in clinical research include:
Enzymopathy characterization: Detecting BPGM protein abnormalities in rare genetic disorders
Reference range establishment: Developing clinical reference ranges for BPGM protein content
Biomarker potential: Exploring BPGM as a biomarker for conditions affecting oxygen transport
Erythrocyte abnormality investigation: Studying BPGM in hematological disorders
High-altitude adaptation research: Examining BPGM expression changes in altitude-related studies
Exercise physiology: Investigating BPGM regulation during athletic training and performance
Anemia research: Characterizing BPGM alterations in different types of anemia
The established ELISA system with its reference range (56.3 ± 9.7 μg/mL in whole blood) provides a foundation for such clinical applications .
Future methodological improvements may include:
Development of monoclonal antibodies for greater consistency and specificity
Site-specific antibodies targeting functional domains of BPGM
Multiplexed detection systems for simultaneous analysis of BPGM and related proteins
Live-cell imaging techniques using non-interfering antibody fragments
Microfluidic platforms for high-throughput BPGM quantification
Automated image analysis algorithms for standardized immunofluorescence quantification
Single-cell analysis techniques to examine BPGM heterogeneity within erythrocyte populations
Nanobody development for improved penetration and reduced interference
These advances would expand the utility and reliability of BPGM antibodies in research applications .
Integration of BPGM antibody data with systems biology requires:
Multi-omics integration: Correlate BPGM protein levels with transcriptomic and metabolomic data
Network analysis: Position BPGM within erythrocyte metabolic networks
Mathematical modeling: Incorporate BPGM data into models of oxygen transport dynamics
Pathway analysis: Examine BPGM in context of glycolytic and related metabolic pathways
Computational prediction: Use structural data to predict BPGM interactions and regulation
Population-level analysis: Study BPGM variation across populations with different environmental adaptations
Time-course studies: Track BPGM dynamics during physiological responses
Data visualization: Develop integrated visualization tools for complex BPGM-related datasets
This integration enables a more comprehensive understanding of BPGM's role in cellular physiology and oxygen transport regulation .
2,3-Bisphosphoglycerate Mutase (BPGM) is a multifunctional enzyme that plays a crucial role in the regulation of hemoglobin oxygen affinity by controlling the levels of its allosteric effector, 2,3-bisphosphoglycerate (2,3-BPG). This enzyme is encoded by the BPGM gene and is involved in both the synthesis and degradation of 2,3-BPG .
BPGM is a member of the phosphoglycerate mutase family and exists as a homodimer. It catalyzes the conversion of 3-phospho-D-glyceroyl phosphate to 2,3-bisphospho-D-glycerate (2,3-BPG), a reaction essential for controlling the concentration of 2,3-BPG within the cell . The enzyme exhibits mutase activity (EC 5.4.2.11) and has phosphoglycerate phosphomutase activity .
2,3-BPG is a small molecule found at high concentrations in red blood cells, where it binds to hemoglobin and decreases its oxygen affinity. This binding is crucial for the efficient release of oxygen to tissues. BPGM’s role in regulating 2,3-BPG levels is therefore vital for maintaining proper oxygen delivery throughout the body .
The BPGM gene is located on chromosome 7 and has multiple alternatively spliced variants encoding the same protein . Mutations in this gene can lead to hemolytic anemia, a condition characterized by the destruction of red blood cells . Additionally, BPGM is associated with diseases such as Erythrocytosis, Familial, 8, and Autosomal Recessive Secondary Polycythemia .
Mouse anti-human BPGM antibodies are monoclonal antibodies used in various research applications, including Western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA) . These antibodies are specific for an epitope within the internal region of the human BPGM protein and are used to detect BPGM expression in different tissues and cell types .